Esther O. Hoop

Dr. Molewaterplein 40, PO Box 2040
Rotterdam, ZH 3000CA, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Response to the Letter to the Editor Re: "Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC".

Response to the Letter to the Editor Re: "Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC".

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 05, 2026

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2026

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: March 10, 2026

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.

Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 02, 2025

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Sex Impacts Progression-Free Survival of Alectinib through Drug Exposure in Patients with ALK-Positive Non-Small Cell Lung Cancer.

Journal: Cancer communications (London, England)

Published: November 03, 2025

Improving Shared Decision-Making in Early Phase Clinical Trials and Palliative Care: A Prospective Study on the Impact of an Online Value Clarification Tool Intervention.

Improving Shared Decision-Making in Early Phase Clinical Trials and Palliative Care: A Prospective Study on the Impact of an Online Value Clarification Tool Intervention.

Journal: Psycho-oncology

Published: February 14, 2025

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 04, 2025

The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.

The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.

Journal: EClinicalMedicine

Published: October 10, 2024

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.

Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.

Journal: EClinicalMedicine

Published: September 05, 2024

The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.

The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.

Journal: International journal of cancer

Published: January 09, 2024

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.

Journal: EBioMedicine

Published: November 01, 2023

CBD-oil as a potential solution in case of severe tamoxifen-related side effects.

CBD-oil as a potential solution in case of severe tamoxifen-related side effects.

Journal: NPJ breast cancer

Published: February 06, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026